logo
Plus   Neg
Share
Email

Hikma Pharma Backs FY Guidance, Remains Confident In Outlook

UK-based pharma group, Hikma Pharmaceuticals PLC (HIK.L, HKMPY), on Friday, in its recent trading update, said it is reiterating its full-year guidance for 2019, and that it remains confident in the outlook for the Group.

The group also said it witnessed good demand for its product portfolio and recent product launches across its three businesses, while it continued to focus on cost reduction.

The Group's Injectables business is performing well and are on track to deliver good growth this year in MENA and Europe, especially in its top MENA markets.

The Generics business had a strong start to the year, in line with its expectations, and continues to expect revenues in the range of $650 million - $700 million.

Hikma said it continues to expect Branded revenue growth to be in the mid-single digits in constant currency in 2019, as it delivers good growth with demand in some of its key markets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boeing (BA) will consider changing the name of the 737 MAX following its global grounding on safety concerns after two fatal crashes involving the jets in Ethiopia and Indonesia. Chief Financial Officer Greg Smith revealed this in an interview to Bloomberg on the sidelines of the Paris Air Show. He... Workers at Volkswagen AG's only factory in the U.S. have voted against forming a factory-wide union, dealing yet another blow to efforts by the United Auto Workers union to organize plants owned by foreign automakers. According to preliminary results announced on Friday, 833 workers at Volkswagen's plant in Chattanooga, Tennessee, reportedly voted against union representation. International Business Machines Corp. and Cúram Software, acquired by the tech giant in 2011, have agreed to pay $14.8 million to settle alleged violations of the False Claims Act, the Justice Department said in a statement. According to the DOJ, IBM and Cúram allegedly made material misrepresentations to the State of Maryland during a contract award process in 2011 and 2012.
Follow RTT